FDA Drug Recalls

Recalls / Class I

Class ID-381-2014

Class I— FDA's most serious classification, issued when there is a reasonable probability that use of or exposure to the drug will cause serious adverse health consequences or death.

Product

0.75% Bupivacaine HCl Injection, USP, 7.5 mg/mL, 30 mL, Single-dose, Hospira Inc., Lake Forest, IL 60045, NDC 0409-1165-02

Brand name
Bupivacaine Hydrochloride
Generic name
Bupivacaine Hydrochloride
Active ingredient
Bupivacaine Hydrochloride
Route
Epidural, Infiltration, Intracaudal, Perineural
NDCs
0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-1165, 0409-9043, 0409-9046, 0409-9045, 0409-9042
FDA application
ANDA070583
Affected lot / code info
Lot # 23-338-DK, Exp. 11/14

Why it was recalled

Presence of particulate matter: visible free floating and partially embedded particulate matter in the glass vials.

Recalling firm

Firm
Hospira Inc.
Manufacturer
Hospira, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
275 N Field Dr, N/A, Lake Forest, Illinois 60045-2579

Distribution

Quantity
119,600 vials
Distribution pattern
Nationwide

Timeline

Recall initiated
2013-07-12
FDA classified
2013-12-18
Posted by FDA
2013-12-25
Terminated
2015-02-03
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-381-2014. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class I recall: Bupivacaine Hydrochloride · FDA Drug Recalls